Video - Results from #30

Clinical Trials For My Patients - Prostate Cancer VL

Evaluating the Benefit of Rucaparib and Enzalutamide Combination Therapy Vs. Enzalutamide Alone for the Treatment of mCRPC - the Phase III CASPAR Trial - Arpit Rao Details The University of Minnesota has recently launched the CASPAR randomized Phase III clinical trial of enzalutamide and rucaparib versus enzalutamide and placebo in first-line metastatic castrate-resistant prostate cancer (CRPC). Alicia Morgans is joined by Arpit Rao from the Univesity of Minnesota to discuss the launch and the initial success of this new trial. Biographies: Arpit Rao, MD, MBBS, Assi...
Intensive Androgen Deprivation in High-Risk Biochemically Recurrent Prostate Cancer Patients - Alliance Foundation Trial (AFT19) - Rahul Aggarwal Details Joining Alicia Morgans to highlight The Alliance Foundation (AFT-19) trial is Rahul Aggarwal from the UCSF Helen Diller Family Comprehensive Cancer Center. The AFT-19 trial started enrolling in March 2017 and is looking at intensive androgen deprivation therapy (ADT) in high-risk biochemically recurrent prostate cancer (BCRP) patients. It is a randomized open-label, three-arm phase 3 study. AFT-19...
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz Details Alicia Morgans welcomes Michael Morris and Lawrence Schwartz to discuss the Prostate Cancer Working Group criteria as a refresher for investigators who are treating men with prostate cancer in clinical trials. Biographies: Michael J. Morris, MD., is the Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section Head, Division of Solid Tumor Oncology, Memorial Sloan Ketteri...
The DORA Trial, Comparing Overall Survival in Patients Treated with Docetaxel vs. Docetaxel plus Radium-223 - Michael Morris Details Michael Morris, Professor of Medicine and GU Medical Oncologist, Memorial Sloan Kettering Cancer Center joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to discuss the DORA trial. Michael Morris is The DORA trial principal investigator for this Prostate Cancer Clinical Trials Consortium (PCCTC) trial. The primary objective of this study is to compare...
Count Me In! The Metastatic Prostate Cancer Project - Eliezer Van Allen Details Eli Van Allen shares details on The Metastatic Prostate Cancer Project, a project part of a larger nationwide genomic research project called "Count Me In" for men with advanced or metastatic prostate cancer. The Metastatic Prostate Cancer Project takes a new approach to cancer research in which researchers partner directly with men with metastatic and/or advanced prostate cancer, who share their...
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran Details Misha Beltran shares details on the Department of Defense grant, a collaboration with Scott Tagawa and Neil Bander at Weill Cornell, and now a continuing effort at the Dana-Farber Cancer Institute. This grant is providing funding to really hone in on the therapeutic side of who are the patients most likely to benefit from PSMA scanning. Focusing on better treatment options for these patients and w...
Current Landscape of Prostate Cancer Clinical Trials - Alliance Cooperative Group - Michael J. Morris Details Michael Morris joins Alicia Morgans for a conversation on the focus of the GU Committee of the Alliance Cooperative Group that is led by Michael Morris. While there is a continued focus on advanced prostate cancer, there is an expected readout on a 12-year study in early disease, the CALGB 90203. CALGB 90203 (Alliance) looked at radical prostatectomy (RP) with or without neoadjuvant chemohormonal...
STARTAR Trial: Systemic Therapy in Salvage Setting for Prostate Cancer- Tian Zhang Details (Length of Discussion: 8 min) Tian Zhang discusses with Alicia Morgans the STARTAR trial, a phase 2 enrolling high risk prostate cancer patients with Gleason 7 T3 or Gleason 8-10 who have developed PSA recurrence and adding systemic agents to standard of care with the goal of extending the lives of this patient population. They discuss logistics for patients who may qualify for this trial. Biograp...

Clinical Trials For My Patients - Prostate Cancer VL

Login